Elevated IGF-1 levels are associated with accelerated bone age advancement during growth hormone therapy in children: a multicenter cohort study

What Was Tested

Researchers studied IGF-1 LR3 in this observational study publication.

Who Took Part

The abstract describes 1,944 children taking part.

PubMed indexes the participants as young children, children and teenagers, both men and women.

This multicenter observational study included 1,944 children with idiopathic growth hormone deficiency (IGHD), idiopathic short stature (ISS), or small for gestational age (SGA) enrolled in the LG Growth Study registry between 2020 and 2024.

BA advancement was defined as the first occurrence of a BA-to-chronological age ratio (BA/CA) >1 during follow-up.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the IGF-1 LR3 study over different clinics and patient groups.

Additional subgroup analyses according to age, sex, diagnosis, and GHD severity were performed.

A sensitivity analysis using BA/CA >1.2 was also conducted.

What Was Measured

The subject headings attached to it are Insulin-Like Growth Factor I, Human Growth Hormone, Infant, Small for Gestational Age, Age Determination by Skeleton, Bone Development, Dwarfism, Pituitary and Cohort Studies.

Author keywords: IGF-1 SDS, bone age advancement, growth hormone therapy, idiopathic short stature and pediatric endocrinology.

What This Means in Plain Language

The paper is a multicenter study of IGF-1 LR3 in 1,944 children.

With several hundred people or more, it is a fairly large study for this kind of research.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Frontiers in endocrinology), a journal based in Switzerland.

More context: the IGF-1 LR3 compound page, all human trials.